ClinicalTrials.gg
CompletedNCT03972280Updated May 26, 2023

Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis

A Phase 1 interventional study of Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody in Hidradenitis Suppurativa and Palmoplantar Pustulosis, sponsored by CSL Behring. Completed at 11 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-05-26.

Sponsored by CSL Behring (part of CSL Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 33 studies in Hidradenitis Suppurativa with a site in Australia — 4 open to participants now, 11 under way, 6 of them phase 3. Hidradenitis Suppurativa · Australia.

Enrollment
31st of 33
39 · median 210
Started
2019
with 3 others
Phase 1
2 of 33
none open now
Registered
4th of 33
by date
Lead sponsor
1 of 33
CSL Behring

Among the 33 studies in Hidradenitis Suppurativa with a site in Australia, this one is the 31st largest by enrollment, is one of 4 that started in 2019, is one of 2 in phase 1, and was the 4th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

4 of the 33 studies in Hidradenitis Suppurativa with a site in Australia are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Hidradenitis Suppurativa with a site in Australia, or all of them as a file.
02

Study summary

Study CSL324_1002 will investigate the safety and pharmacokinetics of repeat doses of CSL324 in subjects with hidradenitis suppurativa and palmoplantar pustulosis. CSL324 is a novel, recombinant therapy that may treat diseases caused by increased numbers of neutrophils at sites of inflammation.

03

Conditions studied

  • Hidradenitis Suppurativa
  • Palmoplantar Pustulosis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects between 18 and 75 years of age, inclusive
  • Confirmed clinical diagnosis of moderate to severe HS as per International Hidradenitis Suppurativa Severity Score System (IHS4) guidelines (ie, IHS4 ≥ 4)
  • PPP differentiated from other forms of pustulosis
  • Psoriasis with a Palmoplantar Pustulosis Psoriasis Area and Severity Index (ppPASI) score of ≥ 12.
  • Subjects with HS only: inadequate response to at least a 3-month (90 days) trial of oral antibiotics for treatment of HS
  • Subjects with PPP only: confirmed clinical diagnosis of PPP at least 6 months before Screening and inadequate response to topical therapy, phototherapy, and / or previous systemic therapy for the treatment of PPP

Exclusion criteria

Exclusion Criteria:

  • Treatment with any medications and therapies not permitted during the study.
  • History of myeloproliferative disease.
  • within 5 years at Screening with the exception of nonmelanoma skin cancer, carcinoma in situ, or prostate cancer not requiring treatment.
  • Current, or a recent history of, uncontrolled renal, hepatic(including currently active virus and / or virus), hematologic, endocrine, pulmonary, psychiatric, or cardiac disease, assessed as potentially having an effect on study outcomes as determined by the Investigator and / or Sponsor.
  • Congenital or acquired condition(s), including infection.
  • Clinical signs of active infection and / or fever > 38°C during the 7 days before Day 1.
  • Clinically significant abnormalities on physical examination, , or laboratory assessments, or neutropenia (defined as \< 2.0 × 109/L) at Screening.
  • Subjects with PPP only: concurrent psoriasis vulgaris (not including scaly scalp and / or ears).
  • Subjects with HS only: > 20 draining fistulas."
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Dose Level 1 (HS)

    Dose 1 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS

    Biological: Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody

  • Experimental
    Dose Level 1 (PPP)

    Dose 1 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with PPP

    Biological: Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody

  • Experimental
    Dose Level 1 (Total)

    Dose 1 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS or PPP

    Biological: Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody

  • Experimental
    Dose Level 2 (HS)

    Dose 2 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS

    Biological: Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody

  • Experimental
    Dose Level 2 (PPP)

    Dose 2 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with PPP

    Biological: Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody

  • Experimental
    Dose Level 2 (Total)

    Dose 2 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS or PPP

    Biological: Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody

Interventions

  • BiologicalRecombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody

    Drug pages: Granulocyte Colony-Stimulating Factor · Filgrastim

    Recombinant anti-G-CSF receptor monoclonal antibody is a preservative-free, sterile liquid formulation that is suitable for intravenous infusion

    Also known as: CSL324

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: Up to 24 weeks

  2. TEAEs by severity

    Time frame: Up to 24 weeks

  3. TEAEs by casuality

    Time frame: Up to 24 weeks

  4. Incidence of adverse events of special interest (AESIs): Grade 3 and 4 neutropenia

    Time frame: Up to 24 weeks

  5. AESIs: Grade 3 and 4 neutropenia by causality

    Time frame: Up to 24 weeks

  6. Incidence of AESIs: Grade 3 and 4 infection

    Time frame: Up to 24 weeks

  7. AESIs: Grade 3 and 4 infection by causality

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Maximum concentration (Cmax) of CSL324 in serum for the first dose administered

    Time frame: Up to 22 days after dose

  2. Time to maximum concentration (Tmax) of CSL324 in serum for the first dose administered

    Time frame: Up to 22 days after dose

  3. Area under the concentration-time curve during a dosing interval (AUCtau) of CSL324 in serum for the first dose administered

    Time frame: Up to 22 days after dose

  4. Cmax of CSL324 in serum for the last dose administered

    Time frame: Up to 22 days after dose

  5. Tmax of CSL324 in serum for the last dose administered

    Time frame: Up to 84 days after dose

  6. AUCtau of CSL324 in serum for the last dose administered

    Time frame: Up to 22 days after dose

  7. Half life (t½) of CSL324 in serum for the last dose administered

    Time frame: Up to 84 days after dose

  8. Total systemic clearance (CLtot) after intravenous dosing of CSL324 in serum for the last dose administered

    Time frame: Up to 22 days after dose

  9. Volume of distribution after intravenous dosing during the terminal elimination phase ( Vz) of CSL324 in serum for the last dose administered

    Time frame: Up to 22 days after dose

  10. Ctrough of CSL324 for each dose of CSL324 administered

    Time frame: Up to 22 days after each dose

  11. Accumulation ratio for AUCtau (ratio between AUCtau of the last dose and of the first dose) and accumulation ratio for Cmax (ratio between Cmax of the last dose and of the first dose)

    Time frame: Up to 22 days after each dose

  12. Presence of anti-CSL324 antibodies in serum

    Time frame: Up to 168 days

07

Study locations

11 sites
  • Holdsworth House Medical Practice
    Darlinghurst, 2010, Australia
  • Fremantle Dermatology
    Fremantle, 6160, Australia
  • The Royal Melbourne Hospital
    Parkville, 3052, Australia
  • Westmead Hospital
    Westmead, 2145, Australia
  • Bispebjerg Hospital
    Copenhagen, 2400, Denmark
  • Gentofte Hospital
    Hellerup, 2900, Denmark
  • Zealand University Hospital
    Roskilde, 4000, Denmark
  • Charité - Universitätsmedizin Berlin
    Berlin, 10117, Germany
  • St. Josef Hospital
    Bochum, 44791, Germany
  • Klinikum Darmstadt
    Darmstadt, 64283, Germany
  • Universitätsklinikum Carl Gustav Carus
    Dresden, 01307, Germany
08

References and documents

Individual participant data

Plan to share: Yes — CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

Supporting information: Study protocol, Statistical analysis plan

Time frame: IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.

Access criteria: Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee. An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee. The requesting party must execute an appropriate data sharing agreement before IPD will be made available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Oct 2022, 39 months.

Of 20 phase 1 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 39 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2019
First posted
Jun 3, 2019
StartActual
Jul 4, 2019
Primary completionActual
Oct 4, 2022
CompletionActual
Oct 4, 2022
Last update
May 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03972280
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Jun 3, 2019
Start date
Jul 4, 2019
Primary completion
Oct 4, 2022
Completion
Oct 4, 2022
Last update
May 26, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Granulocyte Colony-Stimulating Factor · Filgrastim

Start the discussion